GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
Latest Information Update: 10 Jan 2023
At a glance
- Drugs Itacitinib (Primary) ; Methylprednisolone; Prednisone
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms GRAVITAS-301
- Sponsors Incyte Corporation
- 05 Jan 2023 Results published in the Journal of Clinical Pharmacology
- 01 Aug 2022 Results deriving Plasma samples from (identification cohort; NCT02614612, n=25) and deriving data fromNCT03139604- a validation cohort; evaluating biomarker signature predicting complete response to itacitinib and corticosteroids in acute graft-versus-host disease, published in the British Journal of Haematology
- 23 Sep 2020 Status changed from active, no longer recruiting to completed.